The identification of HRAS mutations as a new pathogenetic driver in sporadic PCC opens up the possibility of new therapeutic approaches—though in most cases surgical removal seems likely to be the treatment of choice. BRAF mutations are found in multiple cancer types (Figure 1), notably those that are also associated with mutations in isoforms of RAS (i.e., malignant melanoma, colorectal cancer). Here, HRAS is linked to adrenal gland pheochromocytoma.